A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL)

被引：5
|
作者：
Salles, Gilles
Schuster, Stephen J.
Fischer, Luca
Kuruvilla, John
Patten, Piers E. M.
Tresckow, Bastianvon
Smith, Sonali M.
Jiminez Ubieto, Ana Isabel
Davis, Keith L.
Nagar, Saurabh P.
Zhang, Jie
Bollu, Vamsi
Jousseaume, Etienne
Ramos, Roberto
Wang, Yucai
Link, Brian K.
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-145870
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1349
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma
    Dumontet, C
    Morschhauser, F
    Solal-Celigny, P
    Bouafia, F
    Bourgeois, E
    Thieblemont, C
    Leleu, X
    Hequet, O
    Salles, G
    Coiffier, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 772 - 778
  • [22] Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study
    Casulo, Carla
    Larson, Melissa C.
    Lunde, Julianne J.
    Habermann, Thomas M.
    Lossos, Izidore S.
    Wang, Yucai
    Nastoupil, Loretta J.
    Strouse, Christopher
    Chihara, Dai
    Martin, Peter
    Cohen, Jonathon B.
    Kahl, Brad S.
    Burack, W. Richard
    Koff, Jean L.
    Mun, Yong
    Masaquel, Anthony
    Wu, Mei
    Wei, Michael C.
    Shewade, Ashwini
    Li, Jia
    Cerhan, James
    Flowers, Christopher R.
    Link, Brian K.
    Maurer, Matthew J.
    LANCET HAEMATOLOGY, 2022, 9 (04): : E289 - E300
  • [23] Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma
    Khanlari, Mahsa
    Wang, Sa A.
    Fowler, Nathan H.
    Tang, Guilin
    Saluja, Karan
    Muzzafar, Tariq
    Medeiros, L. Jeffrey
    Thakral, Beenu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07): : E626 - E629
  • [24] THERAPY OF RELAPSED OR REFRACTORY LOW-GRADE FOLLICULAR LYMPHOMAS - FACTORS ASSOCIATED WITH COMPLETE REMISSION, SURVIVAL AND TIME TO TREATMENT FAILURE
    SPINOLO, JA
    CABANILLAS, F
    DIXON, DO
    KHORANA, SM
    MCLAUGHLIN, P
    VELASQUEZ, WS
    HAGEMEISTER, FB
    REDMAN, JR
    SWAN, F
    ANNALS OF ONCOLOGY, 1992, 3 (03) : 227 - 232
  • [25] Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting
    Andorsky, David
    Chan, Rebecca J.
    Clark, Jamyia
    Ruzicka, Bianca
    Robert, Nicholas James
    Awan, Farrukh T.
    BLOOD, 2019, 134
  • [26] A phase II study of arsenic trioxide in the treatment of relapsed and refractory low-grade lymphomas.
    Furman, RR
    Sirulnik, A
    Kamalu, OO
    Brenner, RB
    Paciucci, PA
    Gabrilove, JL
    Waxman, S
    BLOOD, 2002, 100 (11) : 304B - 304B
  • [27] Is watch and wait still acceptable for patients with low-grade follicular lymphoma?
    Armitage, James O.
    Longo, Dan L.
    BLOOD, 2016, 127 (23) : 2804 - 2808
  • [28] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
    Jacobson, Caron Alyce
    Hemmer, Michael T.
    Hu, Zhen-Huan
    Frank, Matthew Joshua
    Popplewell, Leslie
    Ahmed, Nausheen
    Lin, Yi
    Best, Timothy
    Beygi, Sara
    Miao, Harry H.
    Fu, Christine
    Sun, Fang
    Xu, Hairong
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Efficacy Outcomes of Treatments for Double Relapsed/Refractory Follicular Lymphoma (R/R FL): A Systematic Literature Review
    Kahl, Brad S.
    Patel, Anik R.
    Zaidi, Omer
    Snedecor, Sonya J.
    Purdum, Anna G.
    BLOOD, 2020, 136
  • [30] Treatment Patterns and Health/Economic Outcomes in Relapsed/Refractory Follicular Lymphoma: A Real-World Study
    van der Jagt, Richard
    Hamm, Caroline
    Fleury, Isabelle
    Lambert-Obry, Veronique
    Laliberte, Avril Gouault
    Castonguay, Alex
    Wagner, Dennis
    Toltl, Lisa
    Lachaine, Jean
    BLOOD, 2017, 130
12345